<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39025107</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1678-4227</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Arquivos de neuro-psiquiatria</Title><ISOAbbreviation>Arq Neuropsiquiatr</ISOAbbreviation></Journal><ArticleTitle>Long-COVID olfactory dysfunction: allele E4 of apolipoprotein E as a possible protective factor.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>7</EndPage><MedlinePgn>1-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0044-1788272</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">&#x2003;Olfactory dysfunction (OD) represents a frequent manifestation of the coronavirus disease 2019 (COVID-19). Apolipoprotein E (APOE) is a protein that interacts with the angiotensin-converting enzyme receptor, essential for viral entry into the cell. Previous publications have suggested a possible role of APOE in COVID-19 severity. As far as we know, no publications found significant associations between this disease's severity, OD, and APOE polymorphisms (E2, E3, and E4).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">&#x2003;To analyze the epidemiology of OD and its relationship with APOE polymorphisms in a cohort of Long-COVID patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">&#x2003;We conducted a prospective cohort study with patients followed in a post-COVID neurological outpatient clinic, with OD being defined as a subjective reduction of olfactory function after infection, and persistent OD being defined when the complaint lasted more than 3 months after the COVID-19 infection resolution. This cross-sectional study is part of a large research with previously reported data focusing on the cognitive performance of our sample.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">&#x2003;The final sample comprised 221 patients, among whom 186 collected blood samples for APOE genotyping. The persistent OD group was younger and had a lower hospitalization rate during the acute phase of the disease (<i>p</i>&#x2009;&lt;&#x2009;0.001). Furthermore, the APOE variant E4 allele frequency was lower in this group (<i>p</i>&#x2009;=&#x2009;0.035). This study evaluated OD in an outpatient population with COVID-19. In the current literature on this disease, anosmia is associated with better clinical outcomes and the E4 allele is associated with worse outcomes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">&#x2003;Our study provides new information to these correlations, suggesting APOE E4 as a protective factor for OD.</AbstractText><CopyrightInformation>The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Danilo Nunes</ForeName><Initials>DN</Initials><Identifier Source="ORCID">0000-0003-1748-6695</Identifier><AffiliationInfo><Affiliation>Universidade Federal do Cear&#xe1;, Faculdade de Medicina, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavares-J&#xfa;nior</LastName><ForeName>Jos&#xe9; Wagner Leonel</ForeName><Initials>JWL</Initials><Identifier Source="ORCID">0000-0002-7405-4998</Identifier><AffiliationInfo><Affiliation>Universidade Federal do Cear&#xe1;, Faculdade de Medicina, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feitosa</LastName><ForeName>Werbety Lucas Queiroz</ForeName><Initials>WLQ</Initials><Identifier Source="ORCID">0000-0003-1154-257X</Identifier><AffiliationInfo><Affiliation>Universidade Federal do Cear&#xe1;, Faculdade de Medicina, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunha</LastName><ForeName>Let&#xed;cia Chaves Vieira</ForeName><Initials>LCV</Initials><Identifier Source="ORCID">0000-0002-1286-7416</Identifier><AffiliationInfo><Affiliation>Universidade Federal do Cear&#xe1;, Faculdade de Medicina, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>Carmem Meyve Pereira</ForeName><Initials>CMP</Initials><Identifier Source="ORCID">0000-0002-4804-6345</Identifier><AffiliationInfo><Affiliation>Universidade Estadual do Cear&#xe1;, Centro de Ci&#xea;ncias da Sa&#xfa;de, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreira-Nunes</LastName><ForeName>Caroline Aquino</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0001-5845-3481</Identifier><AffiliationInfo><Affiliation>Universidade Federal do Cear&#xe1;, N&#xfa;cleo de Pesquisa e Desenvolvimento de Medicamentos, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Jean Breno Silveira da</ForeName><Initials>JBSD</Initials><Identifier Source="ORCID">0000-0002-0838-3195</Identifier><AffiliationInfo><Affiliation>Universidade Federal do Cear&#xe1;, N&#xfa;cleo de Pesquisa e Desenvolvimento de Medicamentos, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sousa</LastName><ForeName>Artur Victor Menezes</ForeName><Initials>AVM</Initials><Identifier Source="ORCID">0000-0001-8007-5667</Identifier><AffiliationInfo><Affiliation>Universidade Federal do Cear&#xe1;, Faculdade de Medicina, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaspar</LastName><ForeName>Safira de Brito</ForeName><Initials>SB</Initials><Identifier Source="ORCID">0000-0003-4992-4442</Identifier><AffiliationInfo><Affiliation>Universidade Estadual do Cear&#xe1;, Centro de Ci&#xea;ncias da Sa&#xfa;de, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobreira</LastName><ForeName>Emmanuelle Silva Tavares</ForeName><Initials>EST</Initials><Identifier Source="ORCID">0000-0002-6017-5107</Identifier><AffiliationInfo><Affiliation>Universidade Federal do Cear&#xe1;, Faculdade de Medicina, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>La&#xed;s Lacerda Brasil de</ForeName><Initials>LLB</Initials><Identifier Source="ORCID">0000-0003-2814-3575</Identifier><AffiliationInfo><Affiliation>Universidade Federal do Cear&#xe1;, N&#xfa;cleo de Pesquisa e Desenvolvimento de Medicamentos, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montenegro</LastName><ForeName>Raquel Carvalho</ForeName><Initials>RC</Initials><Identifier Source="ORCID">0000-0002-3861-293X</Identifier><AffiliationInfo><Affiliation>Universidade Federal do Cear&#xe1;, N&#xfa;cleo de Pesquisa e Desenvolvimento de Medicamentos, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moraes</LastName><ForeName>Maria Elisabete Amaral de</ForeName><Initials>MEA</Initials><Identifier Source="ORCID">0000-0002-6826-8930</Identifier><AffiliationInfo><Affiliation>Universidade Federal do Cear&#xe1;, N&#xfa;cleo de Pesquisa e Desenvolvimento de Medicamentos, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobreira-Neto</LastName><ForeName>Manoel Alves</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9619-6551</Identifier><AffiliationInfo><Affiliation>Universidade Federal do Cear&#xe1;, Faculdade de Medicina, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braga-Neto</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9186-9243</Identifier><AffiliationInfo><Affiliation>Universidade Federal do Cear&#xe1;, Faculdade de Medicina, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidade Estadual do Cear&#xe1;, Centro de Ci&#xea;ncias da Sa&#xfa;de, Fortaleza CE, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Disfun&#xe7;&#xe3;o olfativa na COVID longa: o alelo E4 da apolipoprote&#xed;na E como um poss&#xed;vel fator protetor.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Arq Neuropsiquiatr</MedlineTA><NlmUniqueID>0125444</NlmUniqueID><ISSNLinking>0004-282X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="Y">Olfaction Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065840" MajorTopicYN="N">Protective Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="ANTECEDENTES" NlmCategory="BACKGROUND">&#x2003;A disfun&#xe7;&#xe3;o olfat&#xf3;ria (DO) &#xe9; uma manifesta&#xe7;&#xe3;o frequente da doen&#xe7;a do coronav&#xed;rus 2019 (COVID-19). A apolipoprote&#xed;na E (APOE) &#xe9; uma prote&#xed;na que interage com o receptor da enzima conversora de angiotensina, essencial para a entrada viral na c&#xe9;lula. Publica&#xe7;&#xf5;es anteriores sugeriram um poss&#xed;vel papel da APOE na gravidade da COVID-19. At&#xe9; onde sabemos, nenhuma publica&#xe7;&#xe3;o encontrou associa&#xe7;&#xf5;es significativas entre a gravidade dessa doen&#xe7;a, DO e polimorfismos da APOE (E2, E3 e E4).</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">&#x2003;Analisar a epidemiologia da DO e sua rela&#xe7;&#xe3;o com os polimorfismos do gene APOE em uma coorte de pacientes com COVID longa. M&#xe9;TODOS: &#x2003;Um estudo de coorte prospectiva com pacientes acompanhados em ambulat&#xf3;rio neurol&#xf3;gico p&#xf3;s-COVID, com DO sendo definida como uma redu&#xe7;&#xe3;o subjetiva da fun&#xe7;&#xe3;o olfativa ap&#xf3;s a infec&#xe7;&#xe3;o e a DO persistente sendo definida quando a queixa durou mais de 3 meses ap&#xf3;s a resolu&#xe7;&#xe3;o da infec&#xe7;&#xe3;o por COVID-19. Este estudo transversal &#xe9; parte de uma pesquisa maior com dados anteriormente relatados, focando na performance cognitiva dos pacientes.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">&#x2003;Foram selecionados 221 pacientes para esse estudo, dos quais 186 haviam coletado amostras de sangue para genotipagem APOE. O grupo DO persistente foi mais jovem e apresentou menor taxa de interna&#xe7;&#xe3;o na fase aguda da doen&#xe7;a (<i>p</i>&#x2009;&lt;&#x2009;0,001). Al&#xe9;m disso, a frequ&#xea;ncia do alelo E4 da APOE foi menor nesse grupo (<i>p</i>&#x2009;=&#x2009;0,035). Este estudo avaliou a DO em uma popula&#xe7;&#xe3;o com COVID longa. Na literatura atual sobre essa doen&#xe7;a, a anosmia est&#xe1; associada a melhores desfechos cl&#xed;nicos e o alelo E4 est&#xe1; associado a piores desfechos. CONCLUS&#xe3;O: &#x2003;Nosso estudo acrescenta novas informa&#xe7;&#xf5;es a essas correla&#xe7;&#xf5;es, sugerindo a APOE E4 como um fator de prote&#xe7;&#xe3;o para DO.</AbstractText><CopyrightInformation>The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/).</CopyrightInformation></OtherAbstract><CoiStatement>The authors have no conflict of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>19</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>19</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>18</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39025107</ArticleId><ArticleId IdType="doi">10.1055/s-0044-1788272</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>